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Ion channels are transmembrane proteins that control the movement of ions across
the cell membrane. They are the molecular machines that make neurons excitable by
enabling the initiation and propagation of action potentials (APs). Rapid signaling within
and between neurons requires complex molecular processes that couple the sensing
of membrane voltage or neurotransmitter release to the fast opening and closing of
the ion channel gate. Malfunction of an ion channel’s sensing or gating module can
have disastrous pathological consequences. However, linking molecular changes to the
modulation of neural circuits and ultimately to a physiological or pathological state is
not a straightforward task. It requires precise and sophisticated methods of controlling
the function of ion channels in their native environment. To address this issue we have
developed new photochemical tools that enable the remote control of neuronal ion
channels with light. Due to its optical nature, our approach permits the manipulation of
the nervous system with high spatial, temporal and molecular precision that will help us
understand the link between ion channel function and physiology. In addition, this strategy
may also be used in the clinic for the direct treatment of some neuronal disorders.
Keywords: optochemical genetics, optogenetics, chemical genetics, photopharmacology, photoswitches, ion
channels, azobenzene
INTRODUCTION
Light is the ideal external stimulus for controlling biological pro-
cesses with high accuracy: it can be manipulated with very high
spatial and temporal precision, it can be projected onto a tissue
from afar and, because cells are typically not intrinsically photo-
sensitive, light can be used as an orthogonal, highly specific stim-
ulus. In the last decade, research in neuroscience has resulted in
an explosion of strategies aiming at optically controlling electri-
cal signals, by rendering ion channels and neurons light-sensitive.
These approaches include naturally photosensitive proteins and
protein domains, caged neurotransmitters and reversible photo-
switches (Kramer et al., 2009; Miesenbock, 2011; Brieke et al.,
2012). The microbial opsins channelrhodospin, halorhodopsin
and archaerhodopsin as well as other light-sensitive ion channels
and transporters have revolutionized neuroscience, by enabling
the remote control of neuronal excitability (Boyden et al., 2005;
Abbreviations: AAQ, acrylamide-azobenzene-quaternary ammonium; AIS, Axon
Initial Segment; BzAQ, Benzylamide-azobenzene-quaternary ammonium; Cav,
voltage-gated calcium channel; DENAQ, diethylamine-azobenzene-quaternary
ammonium; DREADDs, designer receptors exclusively activated by designer
drugs; GABARs, gamma-amino butyric acid receptors; HCN, hyperpolarization-
activated cyclic nucleotide-gated; iGluR, ionotropic glutamate receptor; Kir,
inward-rectifier potassium channel; Kv, voltage-gated potassium channel; MAQ,
maleimide-azobenzene-quaternary ammonium; nAChR, nicotinic acetylcholine
receptor; Nav, voltage-gated sodium channel; PCL, photochromic ligand;
PhENAQ, phenylethylamine-azobenzene-quaternary ammonium; PrAQ, propyl-
azobenzene-quaternary ammonium; PSAM, pharmacologically selective actuator
modules; PSEM, pharmacologically selective effector molecules; PTL, pho-
toswitchable tethered ligand; QA, quaternary ammonium; QAQ, quaternary
ammonium-azobenzene-quaternary ammonium; RASSLs, receptors activated
solely by synthetic ligands; RGC, retinal ganglion cell.
Zhang et al., 2007; Chow et al., 2010). The incredible suc-
cess of these optogenetic tools lies in their versatility (they are
one-component systems, as the chomophore retinal is naturally
present in all vertebrate tissues) and their ability to be specif-
ically targeted to desired neuronal populations (Fenno et al.,
2011; Yizhar et al., 2011; Dugué et al., 2012). By overriding
the electrical activity of neurons, microbial opsins can bring the
membrane potential closer to or further away from the thresh-
old for AP firing. These opsins can thus be used to link optically
induced changes in activity of defined neurons with resultant cir-
cuit or behavioral effects. While advantageous for comprehending
neural networks at a systems level, the optogenetic approach
is ill-suited for understanding the intrinsic mechanisms regu-
lating neuronal excitability on a molecular and cellular level.
Light-sensitive modules from plants, such as phytochromes, cryp-
tochromes, LOV domains or BLUF domains can be genetically
coupled to mammalian proteins in order to gain optical control
over protein–protein interactions, protein or DNA binding, enzy-
matic activity or subcellular protein localization (Möglich and
Moffat, 2010; Pathak et al., 2012). LOV domains have been fused
to the C-terminal fragment of Orai1 calcium channels to remotely
control Ca2+ signaling (Pham et al., 2011). While attractive,
this strategy may prove difficult to transpose to other ion chan-
nels. In contrast, caged compounds and reversible photoswitches
are chemical molecules that have been used by neuroscientists
to modulate the activity of endogenous ion channels in neu-
rons (Goeldner and Givens, 2005). Cages allow for the photore-
lease of neurotransmitters and secondary messengers, triggering
signaling events with temporal and spatial precision (Ellis-Davies,
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2007; Warther et al., 2010). However, since uncaging is an irre-
versible photochemical process, the duration of the elicited effect
is dependent on the kinetics of diffusion or re-uptake of the
photoreleased molecule. On the other hand, chemical photo-
switches (Gorostiza and Isacoff, 2008; Beharry andWoolley, 2011;
Fehrentz et al., 2011) can be used to modulate the activity of ion
channels in a reversible fashion, allowing for many rounds of acti-
vation/deactivation (or inhibition/disinhibition). In this review
we will describe our recent work on developing both one- and
two-component photoswitchable systems for the optical control
of voltage-gated ion channels and neuronal excitability.
ONE-COMPONENT SYSTEMS: DEVELOPMENT AND TUNING
OF PHOTOCHROMIC LIGANDS
Photochromic ligands (PCLs) are light-sensitive molecules
that can photo-isomerize after absorption of a photon.
Photoisomerization induces a modification of the spectral, chem-
ical, electronic and steric properties of the ligand, in a manner
that can affect its biological activity (Beharry and Woolley, 2011;
Fehrentz et al., 2011). Several properties of azobenzene havemade
it the most-commonly used photoswitch for biological applica-
tions: (1) the trans to cis photoisomerization results in a drastic
change in geometry (from planar to twisted, Figure 1A) and
polarity (from ∼0 to 3 Debye) (2) the absorption spectra of the
two isomers are different enough (Figure 1B) to allow nearly-full
conversion to cis or trans under the appropriate light conditions;
(3) azobenzenes are relatively small, simple chemical moieties that
can easily be conjugated to various ligands; (4) photoisomeriza-
tion occurs on a picosecond time scale, orders of magnitude faster
than most biological processes, and (5) azobenzenes are very
photostable, allowing many cycles of photoisomerization without
fatigue. Because the trans isomer is thermodynamically more sta-
ble than the cis isomer, it is the highly predominant form in the
dark (>99.99%).
Photoregulation of ion channels using PCLs was pioneered
with the nicotinic acetylcholine receptor (nAChR) in the late
1960s (Deal et al., 1969; Bartels et al., 1971; Lester et al., 1979;
Krouse et al., 1985) but only recently adapted to other ion
FIGURE 1 | Photoswitchable blockers for voltage-gated potassium
channels. (A) Chemical structures of trans (left) and cis (right) AAQ
(Acrylamide-Azobenzene-Quaternary ammonium). The quaternary
ammonium moiety (ligand) is highlighted by a yellow sphere.
(B) Absorption spectrum of QAQ (Quaternary ammonium-Azobenzene-
Quaternary ammonium) in the dark (∼100% trans) and during
illumination with 380 nm light (mostly cis). (C) Scheme of a trans
blocker. The blocker binds to the intracellular vestibule and blocks ion
conduction through voltage-gated potassium channels in the trans
configuration (500 nm light or darkness) but not after photoisomerization
to cis (380 nm). (D) Example of a voltage-clamp recording of current
through voltage-gated potassium channels after depolarization of the
membrane, using a trans blocker under 500 or 380 nm light illumination.
(E) Scheme of a cis blocker. The blocker binds to the intracellular
vestibule and blocks ion conduction through voltage-gated potassium
channels in the cis configuration (380 nm light) but not in the dark
or after photoisomerization to trans (500 nm). (F) Example of a
voltage-clamp recording of current through voltage-gated potassium
channels after depolarization of the membrane, using a cis blocker under
500 or 380 nm light illumination. : thermal relaxation in the dark.
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channels, such as the ionotropic glutamate (Volgraf et al., 2007;
Stawski et al., 2012) and gamma-amino butyric acid receptors
(GABARs) (Stein et al., 2012; Yue et al., 2012). Following a simi-
lar strategy, we have developed a small library of PCLs that block
voltage-gated potassium channels (Kvs) in a photo-reversible
fashion (Fortin et al., 2008; Banghart et al., 2009; Mourot et al.,
2011, 2012; Fehrentz et al., 2012). Quaternary ammoniums (QAs)
inhibit Kvs by entering the intracellular vestibule and blocking K+
conduction (Choi et al., 1993). We designed photoswitchable Kv
blockers with a central azobenzene core, flanked on one side by
a QA “head” and on the other side by a hydrophobic “tail”. The
initial “tail” was an acrylamide moiety, and the compound was
named Acrylamide-Azobenzene-Quaternary ammonium (AAQ)
(Figure 1A) (Fortin et al., 2008). The reactive acrylamide group
was chosen because AAQ was originally designed to covalently
attach to the outer mouth of native Kvs (Fortin et al., 2008),
but further investigation revealed that, due to its hydrophobic
“tail,” AAQ was in fact able to cross the cell membrane and
non-covalently bind to the internal vestibule (Banghart et al.,
2009). AAQ is a trans blocker of Kvs, that is, the trans isomer
has a much higher affinity for the internal vestibule than the cis
form. In the dark or under 500 nm illumination, channels will
be blocked by AAQ, whereas 380 nm light will relieve the block-
ade and restore K+ conduction (Figures 1C,D). AAQ is a trans
blocker for the Shaker K+ channel, but also for a wide range of
mammalian Kvs heterologously expressed or naturally present in
neurons (Table 1).
Each biological application requires a specific set of char-
acteristics. Photoswitchable Kv blockers can be easily modified
using the power of organic chemistry, enabling us to gener-
ate a small library of compounds with various pharmacological
and photophysical properties (Table 1) (Banghart, 2009; Mourot
et al., 2013). AAQ is a permanently charged molecule that
must cross the cell membrane to photosensitize K+ channels.
Membrane permeation has been experimentally verified for AAQ
(Banghart et al., 2009) and has been observed for other perma-
nently charged drugs like the local anesthetics tonicaine (Wang
et al., 1995) and tetra-pentylammonium (Taglialatela et al., 1991).
In all the aforementioned cases, the charged molecule accumu-
lates inside the cell where it is trapped for hours, more than 24 h
in the case of AAQ loaded into dissociated hippocampal neu-
rons (Banghart et al., 2009). Replacing the acrylamide “tail” with
a more hydrophobic benzylamide moiety results in a molecule
(BzAQ) with better membrane permeation, as evidenced by the
drastic increase in potency when the PCLs are applied outside
cells (see working concentration for AAQ an BzAQ in Table 1)
but a similar potency when the compounds have direct access to
the internal vestibule (Banghart et al., 2009). Doing the opposite,
i.e., replacing the acrylamide chain with amore polar, charged QA
group results in a compound (QAQ) ineffective at crossing the cell
membrane. Of note, some of the most hydrophobic compounds,
e.g., PhENAQ, suffer from lack of water solubility.
Chemical modifications can also affect the pharmacology of
the PCLs. AAQ photosensitizes most, but not all Kvs; for exam-
ple, current through Kv3.1 is not affected by AAQ (Fortin et al.,
2008). Similarly, DENAQ photosensitizes many Kvs but not
Shaker which belongs to the Kv1 family (Mourot et al., 2011).
QAQ, on the other hand, not only photosensitizes Kvs but also
voltage-gated Na+ and Ca2+ channels (Navs and Cavs, respec-
tively) (Mourot et al., 2012), which are structurally related to Kvs
and also blocked by intracellular QAs (Scholz, 2002). Of all the
PCLs tested, only the ones with two QA groups seem to block
Navs (Table 1). The identity of the biologically active isomer also
depends on the chemical nature of the “tail.” For example AAQ,
BzAQ, and QAQ are trans blockers of Kvs, that is, they block pref-
erentially in the trans configuration, but other PCLs such as PrAQ
or PhENAQ are cis blockers (Table 1 and Figures 1E,F). In the
absence of illumination, PCLs exist in only one form: the ther-
mally stable trans isomer. Cis blockers can be advantageous for
certain applications as they are inert in the dark (assuming the
trans isomer does not block at all) and activate only after illumi-
nation with the appropriate wavelength of light. Understanding
the molecular features necessary for the recognition of the cis or
the trans isomer by various ion channels is crucial to the rational
design of more selective PCLs. Alas, this is not a straightforward
task, since it requires the synthesis and screening of a large library
of compounds in addition to molecular modeling of the PCLs
bound to the channel.
The wavelength used to isomerize AAQ from trans to cis is in
the near-UV range (380 nm), which is compatible with biologi-
cal systems. However, there is a clear interest in developing PCLs
with a red-shifted spectrum, as longer wavelengths of light are less
phototoxic and penetrate deeper into tissue. Many of the phenyl
ring substituents are known to alter the spectral characteristics
of azobenzenes and this effect can be rationally utilized to design
novel azobenzene derivatives (Rau, 1973; Beharry and Woolley,
2011). For example, electron donating groups at the ortho or
para positions can red-shift the absorption spectrum of the trans
isomer considerably (Chi et al., 2006; Sadovski et al., 2009;
Beharry et al., 2011, 2008; Stawski et al., 2012). We have designed
PCLs where the amide tail of AAQwas replaced by electron donat-
ing amine tails (see DENAQ and PhENAQ in Table 1). The new
PCLs are red-shifted by up to 100 nm, enabling the photocontrol
of Kvs with blue light (480 nm) (Mourot et al., 2011). The Trauner
group has also developed derivatives of QAQ with electron donat-
ing groups in the ortho position (see 2,2′-dimethoxy QAQ in
Table 1), but this resulted in only a minor red-shift (∼30 nm)
and in some cases compounds that were ineffective at blocking
voltage-gated ion channels (Fehrentz, 2012; Fehrentz et al., 2012).
The internal vestibule of Kvs may be too tight to accommodate
bulky substituents in the ortho position, but seems to accommo-
date rather long, bulky, hydrophilic or hydrophobic “tails” in the
para position.
Once light is turned off, the cis isomer relaxes back to the
more stable trans form, yielding essentially 100% of the trans
isomer. The kinetics of thermal relaxation are highly dependent
on the substituents located on the phenyl rings of the azoben-
zene (Beharry and Woolley, 2011). For example, the half-life of
cis QAQ in aqueous solution (t1/2) is in the 7min range, but
can be extended to hours and even days after adding methyl
groups in the ortho position (see di- and tetra-methyl QAQs in
Table 1). Continuous light exposure is not required to main-
tain these thermo-stable compounds in their cis form. This can
be advantageous in cases where constant illumination would be
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toxic, impractical or simply not technically feasible. Conversely,
thermal relaxation can also be sped up. The fastest thermal relax-
ation reported to date for an azobenzene derivative in water is
in the nanosecond range (Garcia-Amorós et al., 2012). Rapid
thermal relaxation is desirable, since a single wavelength of light
can then be used to quickly toggle the photoswitch between
its two isomers. However, it is not necessarily ideal, since very
intense illumination is required to accumulate enough of a very
short-lived isomer to produce a significant biological effect. The
red-shifted PCLs we have engineered have much faster relax-
ation kinetics than QAQ, too fast, in fact, to be measured using
classical spectrophotometers (Fehrentz et al., 2012), but esti-
mated to be in the hundreds of millisecond range using elec-
trophysiological recordings (Mourot et al., 2011). This value is
in agreement with the reported half-lives in the tens of millisec-
onds range for similar amino-azobenzenes (Chi et al., 2006).
Despite their short half-lives, some red-shifted PCLs block a con-
siderable fraction of the channel’s ionic current, suggesting a
significant accumulation of the cis isomer (Mourot et al., 2011;
Fehrentz et al., 2012). Importantly, because the spectra of the two
amino-azobenzene isomers overlap substantially (Beharry and
Woolley, 2011), light cannot be used to trigger the reverse iso-
merization to the trans form. Therefore, rapid thermal relaxation
is a necessary feature for the rapid and reversible photocon-
trol of neuronal activity with such red-shifted azobenzenes. New
types of red-shifted azobenzenes show a substantial separation
in the spectra of the two isomers, making it possible to use
two different wavelengths of visible light for rapidly accumu-
lating a high percentage of either the cis or the trans isomer
(Beharry et al., 2011; Bléger et al., 2012).
What fraction of the cis isomer can be generated under our
experimental conditions? Since cis and trans azobenzenes have
partially overlapping spectra, illumination produces a photosta-
tionary state with a certain percentage of each isomer. Using the
appropriate wavelength of light, a large fraction of the photo-
switch molecules can be isomerized to cis or to trans (Beharry and
Woolley, 2011). Precise determination using 1H NMR revealed
that up to 95% of the photoswitch can be converted to cis under
illumination with 380 nm (Gorostiza et al., 2007; Banghart and
Trauner, 2013). In order to obtain an estimate of the percentage
of the cis isomer under physiological conditions, we measured
the concentration of two PCLs, AAQ and BzAQ, that blocked
half of the Shaker K+ channel current, both in the dark and
under 380 nm illumination (IC50(dark) and IC50(380 nm), respec-
tively) (Banghart et al., 2009). These two PCLs have identical
azobenzene chromophores, with two amide groups in the para
position, and therefore should have similar photochemical prop-
erties. We found the IC50(380 nm)/IC50(dark) ratio to be 28 and
42 for AAQ and BzAQ, respectively. Assuming cis AAQ and cis
BzAQ bind to Shaker K+ channels with negligible affinity, the per-
centage of the trans molecule under 380 nm light illumination is
1/28 = 3.5% for AAQ, and 1/42 = 2.4% for BzAQ. If the affinity
of cis AAQ or cis BzAQ for Shaker K+ channels is not negligi-
ble, then the percentage of the trans PCL under 380 nm light is
even lower. Hence, it is possible to obtain more than 96% pho-
toisomerization to the cis form using AAQ, BzAQ or other PCLs
with similar photoswitches. As mentioned above, the situation
may be different with quickly relaxing compounds like DENAQ
or PhENAQ.
OPTICAL CONTROL OF ACTION POTENTIAL FIRING WITH
PCLs
The molecular mechanism underlying the initiation and prop-
agation of AP is the opening and closing of voltage-gated ion
channels (Hille, 2001). When excitatory inputs to a neuron trig-
ger a depolarization above the AP initiation threshold (typically
−50mV), Navs quickly open and sodium ions rush into the cell,
depolarizing the membrane even further. After a slight delay,
Navs inactivate and Kvs start to open, thus generating a potas-
sium efflux that repolarizes the cell membrane. Kvs and other
K+ channels (e.g., calcium-activated K+ channels) do not close
immediately after the membrane returns to its resting membrane
voltage, generating a hyperpolarization phase called afterhyper-
polarization (AHP), during which the neuron is refractive to
subsequent AP. Therefore, the influx and efflux of sodium and
potassium ions shape APs, and rapidly photoregulating their flux
should give us control over AP firing.
When neurons are at rest, some Kvs, notably the low-voltage
activated ones, are open and play a role in maintaining and reg-
ulating the membrane potential (Hille, 2001). Blocking them can
result in membrane depolarization and increase neuronal activ-
ity. AAQ, which is a photoswitchable blocker selective for K+
channels, can be used to optically increase neuronal excitability
and induce AP firing (Fortin et al., 2008). In the dark or under
green light, AAQ blocks neuronal Kvs, depolarizes the cell mem-
brane and enables high-frequency firing (Figure 2A). Subsequent
photoisomerization to cis with 380 nm light, which unblocks Kvs,
hyperpolarizes the membrane and reduces neuronal excitabil-
ity. Comparing the AP shapes under both wavelengths of light
clearly shows that the peak is unaltered, while hyperpolarization
is reduced under 500 nm light, consistent with the selective block
of K+ channels (Figure 2B). Optical regulation of membrane
excitability with AAQ works well not only in cultured neurons,
but also in rat cerebellar slices, in the heart central pattern genera-
tor of leeches, as well as inmice retinal neurons in vitro and in vivo
(Fortin et al., 2008; Polosukhina et al., 2012). One limitation of
AAQ is that, in the absence of illumination, the trans configu-
ration dominates, leading to a tonic block of Kvs and potential
cytotoxicity. Cis blockers like PhENAQ could offer significant
advantage by minimizing basal excitation in the dark (Mourot
et al., 2011).
QAQ has a different effect on neuronal excitability: it does not
modulate the resting membrane potential, but prevents AP firing
when neurons receive excitatory inputs, by blocking all voltage-
gated ion channels, i.e., Kvs, Navs and Cavs (Mourot et al., 2012).
When illuminated with 500 nm light, neurons loaded with QAQ
fire a single AP at the onset of current injection, followed by depo-
larization block and absence of repetitive spiking (Figure 2C).
The presence of the first spike can be attributed to the nature
of the molecular interaction between trans QAQ and ion chan-
nels: QAQ is an open-channel blocker, that is, ion channels
must first open before QAQ can bind and block ion conduction
(Hille, 2001; Mourot et al., 2012). Under 380 nm light, ion-
channel block is relieved and neurons can fire at a high-frequency.
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FIGURE 2 | Optical control of AP firing in hippocampal neurons using
PCLs. (A) Current clamp recording of a hippocampal neuron in culture treated
with AAQ, showing the effect of light on neuronal excitability. (B) AP shape in
both wavelength of light for an AAQ-treated hippocampal neuron. (C) Current
clamp recording of a hippocampal neuron in culture loaded with QAQ through
the patch pipette, showing the effect of light on spike inhibition. (D) AP shape
in both wavelength of light for a neuron loaded with QAQ. (E) Patterned
illumination for the optical control of the excitability of a dendritic tree using
QAQ loaded through the patch pipette. The main regions of a neuron are
indicated. Scale bars (A,C) 10mV, 500ms; (B,D) 10mV, 25ms.
Due to the block of both Kvs and Navs, the AP amplitude is
reduced and its half-width increased under 500 nm compared to
380 nm light (Figure 2D). QAQ blocks Navs only partially, yet
it potently silences cells, probably because its blockade of K+
channels potentiates blockade of Na+ channels (Drachman and
Strichartz, 1991).
Neuronal dendrites receive, coordinate and integrate thou-
sands of excitatory and inhibitory inputs (Magee and Johnston,
2005). Inputs are integrated at the level of the soma and APs
are initiated in a specialized, unmyelinated element of the neu-
ron called the axon initial segment (AIS), before they propagate
through the rest of the axon (Kole and Stuart, 2012). In some
neurons, such as hippocampal and cortical pyramidal neurons,
APs can also back-propagate from the soma to the dendrites,
which is essential to many forms of synaptic plasticity (Magee,
1997; Markram, 1997; Magee and Johnston, 2005). The pres-
ence of a high density of specialized voltage-gated ion chan-
nels is essential to the electrical properties of AIS, axons and
dendrites. Yet, manipulating these ion channels in specific sub-
cellular domains of a neuron is technically challenging. Local
perfusion of tetrodotoxin, a specific Nav blocker, has been used
to show that back-propagation of APs is required for the induc-
tion of synaptic plasticity (Magee, 1997), but this can only be
done in large neurons with dendritic trees long-enough to con-
fine tetrodotoxin to the desired location. Membrane-impermeant
ion-channel blockers like QX-314 can also be used to eliminate
excitability in dendrites and axons of single neurons, making it
possible to pharmacologically isolate synaptic from non-synaptic
events and elucidate the composition of the synaptic responses
(Smirnov et al., 1999; Wilent and Contreras, 2005). Because QX-
314 is membrane-impermeant (Strichartz, 1973; Binshtok et al.,
2007), it can be dialyzed into cells through a patch pipette,
but once inside, it cannot be removed; therefore its action is
irreversible. In contrast to chemical ligands, light can be deliv-
ered onto tissues with great spatial resolution, and recent opti-
cal techniques even allow for patterned illumination in three
dimensions (Vaziri and Emiliani, 2012). Therefore, photocon-
vertible ligands such as the ones we have developed could be
extremely useful in understanding the roles of voltage-gated ion
channels in controlling dendritic and axonal excitability, espe-
cially in compact neurons. QAQ, which is essentially a pho-
toswitchable derivative of QX-314 (Mourot et al., 2012), can
open the way to new experimental opportunities. Because light
can be projected with great spatial precision, it might be pos-
sible to control APs in particular parts of a neuron, such as a
branch of the dendritic tree or the AIS (Figure 2E). For exam-
ple, QAQ could be used to reversibly block back-propagating
APs with a cellular precision that is hard to achieve with exter-
nally applied blockers (Magee, 1997), and help evaluate the
contribution of dendritic excitability to synaptic integration and
plasticity.
CELL TARGETINGWITH QAQ
Optogenetic tools have one advantage over PCLs: they can be
targeted to genetically defined cell types using either specific
promoters or cre recombinase-inducible expression systems in
conjunction with transgenic animals expressing cre in specific
population of neurons (Fenno et al., 2011; Yizhar et al., 2011;
Dugué et al., 2012). Cell targeting is essential for establishing
a causal relationship between the activity pattern of a defined
population of neurons and the function of that neuronal popu-
lation at the circuit or behavioral level. Even though QAQ is not
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genetically encodable, we have designed a strategy for delivering
it to a defined sub-population of neurons.
QAQ is a doubly charged (Figure 3A), membrane-
impermeant PCL that does not enter most cells when applied
extracellularly. However, we found that QAQ was able to enter
cells through open TRPV1 and some P2X channels, enabling
the targeted photosensitization of cells expressing either of
these channels (Mourot et al., 2012). TRPV1 channels are
heat-activated channels required for the detection of noxious
heat (Caterina et al., 1997), while P2X receptors are ion channels
activated by extracellular ATP (Valera et al., 1994). One biophysi-
cal property shared by these two ion channel types is their ability
to allow large organic cations to pass through the channel pore
(Khakh et al., 1999; Virginio et al., 1999; Meyers et al., 2003;
Chung et al., 2008; Binshtok et al., 2007). We took advantage of
this property to deliver QAQ into specific cells, utilizing these
channels as “molecular conduits” (Figure 3B).
TRPV1 channels are highly expressed in pain fibers but
scarcely present in the central nervous system (CNS) (Arenkiel
et al., 2008; Cavanaugh et al., 2011). P2X receptors are primar-
ily expressed in the peripheral nervous system and in epithelial
and endothelial tissue, but are also present to some extent at
a few central synapses (Khakh and North, 2006). Because both
channels and their respective agonists, capsaicin and ATP, are
nearly absent from the CNS, heterologous expression of TRPV1
or P2X channels could be used as an orthogonal way of opti-
cally silencing genetically identified neurons with QAQ (Mourot
et al., 2012). Miesenböck and colleagues designed a comparable
optochemical genetic strategy to remotely photoactivate specific
neurons heterologously expressing TRPV1 or P2X channels, using
FIGURE 3 | Cell targeting strategy with QAQ. (A) Chemical structures of
trans (left) and cis (right) QAQ. (B) QAQ is membrane impermeable, but can
enter cells through open TRPV1 or P2XR channels. Once in the cystosol,
QAQ photosensitizes voltage-gated K+, Na+, and Ca2+ channels. (C) Touch-
and pain-sensing neurons innervate the skin and project to the spinal cord.
Their cell bodies are located in the dorsal root ganglia. QAQ can be targeted
specifically to pain-sensing neurons, which contain high densities of TRPV1
channels.
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caged-capsaicin or caged-ATP, in living flies (Zemelman et al.,
2003; Lima and Miesenbock, 2005; Claridge-Chang et al., 2009).
While elegant and powerful, both approaches suffer from the
technical complexities associated with the expression of foreign
genes and the subsequent delivery of photosensitive chemicals.
However, exogenous expression of TRPV1 or P2X receptor
is not always necessary to target QAQ-induced photosensitiv-
ity to specific neurons. We took advantage of the intrinsic
TRPV1 expression pattern to specifically deliver QAQ to pain-
sensing neurons in rodents. Co-application of QAQ and capsaicin
resulted in the selective entry of QAQ into pain-sensing neu-
rons (aka nociceptors) both in vitro and in vivo, without affect-
ing neighboring cells such as touch-sensing neurons, which are
devoid of TRPV1 channels (Mourot et al., 2012). Sensory neu-
rons are pseudo-unipolar neurons, with a peripheral process that
carries AP to the cell body (located in the dorsal root ganglia),
and a central process that carries AP to the post-synaptic neuron
in the spinal cord (Figure 3C). The peripheral axons of nocicep-
tors are usually extremely long and mixed together with other
sensory neurons. Hence it has been extremely difficult to manip-
ulate the activity of these neurons in a specific manner using
current electrophysiological or pharmacological tools. Because
QAQ can enter nociceptors at the level of their cell bodies, their
synaptic terminals or their sensory nerve endings, our method
enables the rapid control of pain signaling with a high degree of
precision. This method will undoubtedly prove useful for under-
standing pain circuitry and pain signaling, in both physiological
and pathological conditions.
TWO-COMPONENT SYSTEMS: DEVELOPMENT OF
DESIGNER PHOTORECEPTORS
The various voltage- and ligand-gated ion channels found in neu-
rons have very distinct biophysical properties as well as different
subcellular and cellular distributions, but often share overlap-
ping pharmacology. The limited selectivity of pharmacological
agents has hindered the understanding of their physiological
roles. Traditional drugs often cannot differentiate between differ-
ent receptor types or subtypes. Some of them, such as toxins, do
show good receptor selectivity, but their temporal action profile
cannot mimic the rapid rise and fall in neurotransmitter concen-
trations in the brain, as they persist in the tissue for an extended
period of time and cannot be washed out quickly. In addition,
the effect of traditional pharmacological agents cannot be easily
restricted to a specific cell type or tissue; for example, there is no
method for selectively controlling post- vs. pre-synaptic recep-
tors. The relationship between receptor function and behavior
can also be studied via the generation of transgenic organisms,
but this strategy lacks temporal specificity and can produce ani-
mal phenotypes where undesirable developmental defects and
compensatory changes are superimposed on the true effects of
receptor removal. The development of spatially and temporally
targeted activation/inactivation of specific receptors will help to
overcome this problem and produce a better understanding of the
function of receptors in adult animals.
A number of chemical genetic strategies have been devel-
oped to overcome the limitations of conventional pharmacology.
They combine the powers of chemistry and genetic targeting
to enable an unparalleled degree of pharmacological specificity
(Rogan and Roth, 2011; Wulff and Arenkiel, 2011). One strategy
involves designing a combination of chemically modified small
molecule ligands andmutant receptors that specifically bind these
ligands. Themodified ligands are considered “orthogonal” in nor-
mal cells, since they should not bind any wild-type receptor,
but only their mutant partner. This approach was first demon-
strated on a mutant κ opiod receptor, which was engineered to
dramatically reduce its affinity for the endogenous ligand dynor-
phin, but still respond to synthetic small molecule drugs (Coward
et al., 1998). This type of receptor activated solely by synthetic
ligands was called a RASSL. The receptor-ligand pair strategy
was later extended to create other mutant G protein-coupled
receptors with lower baseline activity. These second generation
designer receptors exclusively activated by designer drugs were
named DREADDs (Armbruster et al., 2007). Ligand-gated ion
channels, including GABARs (Wulff et al., 2007) and nAChRs
(Magnus et al., 2011) were also engineered to be orthogonal to
certain ligands. In the case of nAChRs, a variety of pharmacologi-
cally selective effector molecules (PSEMs) and pharmacologically
selective actuator modules (PSAMs) were generated, with differ-
ent ionic permeabilities for remotely exciting or silencing targeted
neurons. The mutant receptors may retain their original function,
in which case the receptor-ligand pair is used to define the bio-
logical roles of the receptor (Wulff et al., 2007). Conversely, the
receptor may only possess the ability to bind the orthogonal lig-
and but not the endogenous neurotransmitter, in which case the
receptor becomes orthogonal as well and is used to remote control
cellular signaling or membrane excitability in genetically targeted
cells (Armbruster et al., 2007; Magnus et al., 2011). However,
though this chemical genetic approach has produced highly spe-
cific receptor-ligand combinations that work well both in vitro
and in vivo, it still suffers from the lack of fine spatiotemporal
control of receptor activity, due to the inability to control lig-
and diffusion into or out of a region of interest or manipulate
the dynamics of ligand binding/unbinding. Light is the perfect
modality for achieving such precise spatiotemporal control, as it
allows for micrometer spatial and millisecond temporal resolu-
tion. We thus decided to combine the power of chemical genetics
with the precision of optical control in order to develop a series
of photoswitchable tethered ligands (PTLs) for the optochemical
genetic control of ion channels (Fehrentz et al., 2011).
The PTL strategy involves the genetic engineering of receptors
and their conjugation to a chemical photoswitch, allowing light
to precisely activate or inhibit that receptor subtype in a given
neuronal population. The PTL contains a ligand (agonist or pore
blocker/antagonist) on one end of the molecule, a central pho-
toisomerizable azobenzene core, and a cysteine-reactive group on
the other end of the molecule. The PTL can react with engineered
cysteine point mutations in the ion channel of interest, covalently
tethering the ligand to the receptor. In addition to the shape and
dipole moment changes, the end-to-end distance of the trans and
cis isomers is also substantially different, allowing light to toggle
the ligand in and out of its binding pocket. Photoisomerization
of the PTL thus leads to a reversible activation or inhibition of
the receptor. Such a strategy allows us to control an individ-
ual ion channel subtype in a neuron, i.e., the one containing
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the cysteine mutation, with high spatiotemporal precision, while
leaving native channels unaffected. Importantly, the function-
ality of the mutant receptor should remain unchanged prior
to PTL treatment, but its activity would then be controlled by
light after conjugation of the PTL. Because designer channels
can be genetically targeted, they belong to the family of optoge-
netic tools, even though they need a photochemical co-factor for
functioning.
PTLs were first designed for the voltage-gated Shaker K+
channel, resulting in synthetic photoisomerizable azobenzene-
regulated K+ (SPARK) channels (Banghart et al., 2004; Chambers
et al., 2006) that could be blocked and unblocked by light. SPARK
channels are cysteine-containing mutant Shaker K+ channels,
which can be conjugated to a photoswitchable ligand, maleimide-
azobenzene-quaternary ammonium (MAQ, Figure 4A), contain-
ing the pore blocker QA. QAs not only block K+ channels at
the level of the inner vestibule, but also at an external bind-
ing site located just outside the selectivity filter (Hille, 2001).
After MAQ conjugation, the QA moiety can reach the ion chan-
nel’s outer pore only in the trans but not the cis configuration,
which results in conduction block under 500 nm light or in
the dark, when the PTL is in the trans form (Figures 4B,C).
Illumination with 380 nm light converts the PTL to its shorter
cis form, unblocking the ion channel and allowing for current
flow. At low micromolar concentration, MAQ does not cross the
cell membrane, ensuring specific optical control of the engineered
cysteine mutant channel (Fortin et al., 2011; Sandoz et al., 2012).
Expression of SPARK channels in neurons enabled the photocon-
trol of neuronal activity (Banghart et al., 2004; Chambers et al.,
2006). However, because Shaker is a Drosophila K+ channel, it
is orthogonal to mammalian neurons and is therefore unsuited
for the study of endogenous K+ channel function in the mam-
malian CNS. We have thus decided to transpose the strategy to
mammalian K+ channels. Tethering MAQ onto engineered cys-
teine mutants of Kv1.3, Kv3.1, Kv7.2, Ca2+-activated SK2 and
TREK1 conferred photosensitivity on these K+ channels (Fortin
et al., 2011; Sandoz et al., 2012). These novel light-sensitive chan-
nels are highly interesting targets for optical control. For example,
Kv7.2 is a potassium channel underlying the M-current and has
also been implicated in epilepsy (Brown and Passmore, 2009),
while the calcium-activated SK2 channel modulates excitatory
post-synaptic potentials and contributes to long-term potentia-
tion in the hippocampus (Adelman et al., 2011). TREK1 channels
are polymodal channels, being sensitive to temperature, pressure,
pH and intracellular signaling (Alloui et al., 2006). Specific pho-
tomodulation of TREK1 revealed that they are also activated by
GABAB signaling in the hippocampus (Sandoz et al., 2012).
K+ channels are not the only family of transmembrane pro-
teins that can be targeted with the PTL strategy. We have
recently developed a series of light-regulated neuronal nAChRs
(LinAChRs) which can be conjugated with photoswitchable ago-
nists or antagonists, allowing for powerful bidirectional control
FIGURE 4 | Engineered potassium channels with a photoswitchable
tethered ligand (PTL). (A) Chemical structures of trans (left) and cis
(right) MAQ (Maleimide-Azobenzene-Quaternary ammonium). The
end-to-end distance between the para positions of the azobenzene
shortens by ∼3Å upon isomerization from trans to cis. (B) Scheme of
a genetically-encoded, photoswitchable K+ channel. MAQ is covalently
attached on an engineered cysteine located on the extracellular surface
of a K+ channel. In the extended trans configuration (dark or 500 nm
light), MAQ blocks ion conduction. Photoisomerization to cis with
380 nm light shortens MAQ and relieves block. (C) Current through a
photoswitchable Kv 3.1 channel labeled with MAQ, under both
wavelengths of light.
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of receptor activity (Tochitsky et al., 2012). Given the wide
variety of nAChR subtypes present in the brain and the lack
of specific pharmacology for them, LinAChRs should prove
highly useful in studying the function of nAChRs in the ner-
vous system. Furthermore, controlling specific nAChRs in the
brain may help shed light on their role in nicotine addiction
and various neurodegenerative and neuropsychiatric disorders.
Another major class of channels targeted with PTLs is the glu-
tamate receptor (GluR) family. A series of ionotropic glutamate
receptors belonging to the kainate receptor family (iGluR6) could
be activated by light after conjugation of a photoswitchable ago-
nist to an engineered mutant cysteine residue (Volgraf et al., 2005;
Gorostiza et al., 2007; Numano et al., 2009). The resulting light-
activated glutamate receptors (LiGluRs and HyLighter) enabled
the remote control of neuronal electrical activity both in vitro
(Szobota et al., 2007) and in vivo in zebrafish larvae (Janovjak
et al., 2010; Wyart et al., 2010) and in mice (Caporale et al.,
2011).
The success and relative ease of generating novel light-sensitive
ion channels demonstrate the power of the PTL approach, as
almost any channel or receptor can, in principle, be rendered
light-sensitive by combining existing pharmacological and struc-
tural information. Synthetic organic chemistry can generate
photosensitive variants of existing receptor ligands. Molecular
modeling can then identify a region of interest where cysteine
scanning mutagenesis would determine the optimal position for
PTL attachment. Once a particular channel has been photosen-
sitized, structurally similar relatives can be photosensitized as
well, often simply by transposing the cysteine mutation from one
subtype to another (Fortin et al., 2011; Tochitsky et al., 2012).
A PTL-conjugated receptor can be controlled specifically, with
either an agonist or antagonist/pore blocker, with a spatial and
temporal precision simply impossible with traditional diffusible
ligands. The combination of rational design, specificity and preci-
sion makes the PTL approach a very powerful tool for identifying
the roles of particular ion channel subtypes in complex neural
networks, both in vitro and in vivo.
So far, the designer receptor strategy has mainly been used
in vitro, where gene delivery and conjugation of the PTL onto
the engineered cysteine mutation are relatively staightforward. In
vivo, its use has been restricted to zebrafish larvae where the PTL
can be added to the water where fish swim and absorbed through
the skin (Janovjak et al., 2010;Wyart et al., 2010) and to themouse
retina where the PTL can be easily injected into the vitreous
cavity of the eye (Caporale et al., 2011). Traditional optogenetic
tools (e.g., channelrhodopsin) have an advantage over designer
receptors in this regard, since the photoswitch retinal is naturally
present in cells and does not have to be introduced exogenously.
Nonetheless, designer receptors can be used to answer questions
that would be hard to address with channelrhodopsin. For exam-
ple, engineered receptors can reveal a causal relationship between
receptor activation in a given cell type and the activity of a
neuronal circuit or the induction of a certain behavior. Light-
sensitive designer receptors can also be used to investigate the
function of receptors with different subunit compositions, or the
function of a specific receptor expressed in different cell types.
However, before these new optical tools can be generally used
in mammals in vivo, a certain number of challenges must be
overcome:
Gene delivery: photosensitive ion channels can be overexpressed
in neurons and manipulated with light in order to study their
function, but it is preferable to maintain the endogenous level of
gene expression in order to ensure that the results are physiolog-
ically relevant. Such a system can be created via the generation
of a knock-in animal, where the endogenous channel is replaced
by the cysteine mutant, although this approach is laborious
and costly. Alternatively, the cysteine mutant subunit can be
expressed in a system where it would need to coassemble with
an endogenous wild-type subunit for trafficking to the plasma
membrane. This photoswitchable conditional subunit strategy
was successfully utilized in vitro for the photosensitive TREK1
two pore K+ channel (Sandoz et al., 2012) and should be fea-
sible in vivo for other heteromeric ion channels such as brain
nAChRs. Expression of the cysteine-containing subunit can in
principle be done in the wild-type background, although the
use of a knock-out animal is preferred to maximize the degree
of photocontrol. In vivo gene delivery can be done using lenti-
or adeno-associated (AAV) viral vectors, or the in utero electro-
poration technique (Fenno et al., 2011).
Cell-type specific expression: one method of manipulating genet-
ically defined neuronal subtypes involves the expression of the
gene of interest under the control of cell-type specific promoters.
Another possibility is to use Cre recombinase-inducible expres-
sion systems in conjunction with transgenic animals expressing
Cre in specific neuronal populations. Cre recombinase will cat-
alyze the recombination between two loxP sites, resulting in the
reversal of the gene’s orientation and allowing for the gene’s
mRNA to be transcribed. High levels of cell type specificity can
usually be achieved with this technique (Fenno et al., 2011).
Light delivery: since the advent of optogenetics, different hard-
ware setups have been used to deliver light in vitro and in vivo
(Fenno et al., 2011). Lasers coupled to optic fibers are most
commonly used to deliver light into the brain. The fiber can be
placed either in the same brain area as the virus injection or in
projection targets.
PTL delivery: one of the biggest challenges of our PTL approach
is the delivery of the photoswitch. Because of maleimide’s reac-
tivity, delivery has to be done locally into the brain, using a guide
cannula for example. The cannula can be chronically implanted
into the animal, allowing for the delivery of both the chemical
photoswitch and the optical stimulation fiber to the region of
interest. Since it covalently tethers to its receptor, the PTL can
be applied hours before an experiment, ensuring that the excess
non-conjugated PTL will diffuse or be metabolized. Another
important factor to consider is the efficiency of conjugation,
which depends on the oxidation state of the cysteines. Reducing
agents such as DTT or TCEP have been used in vitro to reduce
cysteines and increase labeling; it is not clear whether these
agents will also be required for in vivo use.
BIOMEDICAL APPLICATIONS
Gene therapy with optogenetic tools has been proposed as a
strategy for restoring vision (Busskamp and Roska, 2011) as well
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as for treating Parkinson’s disease or epilepsy through deep brain
optical stimulation (Gradinaru et al., 2009). Although current
gene therapy trials for CNS diseases have shown good safety, it
is not clear how the human immune system will tolerate the high
levels of microbial opsin expression required for photosensitizing
neurons. In contrast, due to its non-genetic nature, the PCL
approach for photosensitizing neurons should provide a readily
reversible, safe therapeutic strategy. Here we describe the poten-
tial use of PCLs for the treatment of blindness and management
of chronic pain.
VISION
Given that the use of PCLs for clinical applications is limited
by the ability to deliver light to a particular tissue or organ, the
visual system was selected as an ideal clinical target due to the
inherent ease of light delivery to the eye. Restoration of neu-
ral light sensitivity is needed to treat several degenerative retinal
disorders, such as retinitis pigmentosa and age-related macu-
lar degeneration, which are characterized by the progressive loss
of rod and cone photoreceptors, eventually leading to complete
blindness (Jones et al., 2012). In such end-stage blinding dis-
eases, the photoreceptors are absent but other types of neurons
in the retina, including retinal ganglion cells (RGCs), bipolar and
amacrine cells remain intact (Figures 5A,B). We decided to test
whether treatment of the blind retina with AAQ would confer
light sensitivity onto these remaining neurons and whether this
engineered light response could drive visually guided behavior
in vivo.
To evaluate the effect of the PCL, we selected the rd1/rd1
mouse model of end-stage retinitis pigmentosa, in which virtu-
ally all photoreceptors die by 3 months after birth (Sancho-Pelluz
et al., 2008). Prior to AAQ treatment, no light responses were
observed on the multi-electrode array (MEA) (Figure 5C), which
records the activity of dozens of RGCs in vitro. After treatment
with AAQ, we observed a dramatic increase in RGC activity
upon stimulation with 380 nm light, which could be turned off
by subsequent 500 nm illumination (Figure 5D) (Polosukhina
et al., 2012). This pattern of AAQ-mediated light responses was
opposite to what we had previously observed in cultured neu-
rons, where 380 nm light usually decreases neuronal excitability
(Figure 2A). By applying pharmacological synaptic blockers, we
determined that AAQ photosensitized all remaining retinal cell
types, including the inhibitory amacrine cells. After blockade of
inhibitory GABAergic and glycinergic inputs, the RGCs increased
their activity in 500 nm light, consistent with previous findings
from cultured neurons (Polosukhina et al., 2012). The photo-
control of inhibitory amacrine synaptic drive thus appears to be
the major contributor to light-dependent RGC activity after AAQ
treatment.
Amazingly, intraocular injection of AAQ could also restore
visually guided behaviors in rd1 mice in vivo. After the injection,
previously blind mice displayed light aversive locomotory behav-
ior in a turning assay. Additionally, these mice regained a light-
driven pupillary light reflex. Finally, AAQ-injected rd1/rd1 mice
displayed light-dependent changes in locomotory activity in an
open-field assay. The ability of AAQ to restore light perception to
FIGURE 5 | Photosensitizing blind retinas with PCLs. Circuit diagram of
(A) a healthy retina and (B) a retina lacking rod and cone photoreceptors due
to advanced degeneration. Note that retinal ganglion, bipolar and amacrine
cells survive photoreceptor death. (C,D) Multi-electrode array recordings
from a flat-mounted rd1 mouse retina (C) before and (D) after treatment with
300μM AAQ. Top: Color bars representing illumination with 380 nm (violet)
or 500 nm (green) light. Middle: Raster plot of RGC activity. Bottom: Average
RGC firing rate (bin size = 100ms).
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blind mice in vivomakes the PCL approach a promising potential
therapy for end-stage retinitis pigmentosa and age-related macu-
lar degeneration. Novel Kv PCLs such as DENAQ and PHENAQ
(Mourot et al., 2011) have a red-shifted absorption spectrum and
faster thermal relaxation compared to AAQ. These molecules may
be better clinical candidates due to their ability to respond to
visible rather than UV light and be controlled with a single wave-
length of light. Further chemical synthesis and screening of our
existing PCL library should allow us to develop compounds with
optimal properties for vision restoration—ones sensitive to dim
visible light, safe for intraocular use and producing long-lasting
photosensitivity in vivo after a single injection.
CHRONIC PAIN
Local anesthetics such as lidocaine are potent silencers of neu-
ronal activity and extremely useful clinical drugs for managing
acute pain. However, these drugs are not well suited to the treat-
ment of persistent, chronic pain because (1) they lack specificity
for motor vs. sensory neurons and also for different sensory
modalities (e.g., touch sensation) (2) block duration or inten-
sity cannot be regulated (Roberson et al., 2011). Because QAQ
is selective for pain-sensing neurons, it may block nociception
without affecting motor axons or other sensations. Moreover,
because QAQ blockade can be precisely modulated by changing
light wavelength or intensity, it may be possible to photo-titrate
the analgesic effect at will.
QAQ could be administered in combination with capsaicin to
selectively block TRPV1-containing nociceptors. A similar strat-
egy has been proposed for the membrane-impermeant lidocaine
derivative QX-314, which produces long-lasting selective analge-
sia (Binshtok et al., 2007; Kim et al., 2010). However, because
capsaicin activates TRPV1 channels and produces pain, it may
be desirable to target nociceptors by other means (Roberson
et al., 2011). In pathological pain conditions, nociceptors become
hyperactive. Our experiments with QAQ suggest that the basal
activity of TRPV1 channels increases in electrically hyperactive
neurons (Mourot et al., 2012). If this is the case, capsaicin may
not be needed, and QAQ may be self-targeted to the most active
nociceptors, i.e., the ones that need to be silenced the most. This
finding may explain why QX-314 alone, which is normally unable
to cross neuronal membranes, is effective for recovery after spinal
cord injury (Agrawal and Fehlings, 1997) and in animal models
of neuropathic pain (Omana-Zapata et al., 1997).
Photoregulation of pain sensation in vivo requires light deliv-
ery to the targeted neuronal tissue. Because the terminal endings
of nociceptive neurons are located just below the skin, an external
light source could be used after topical application of QAQ. The
cornea, which is fully transparent and highly-enriched in sensory
fibers, is the ideal peripheral target, as evidenced by the potent
optical regulation of touch-evoked responses seen in living rats
(Mourot et al., 2012). Red-shifted derivatives of QAQ (Mourot
et al., 2011) may be more appropriate for the optical regulation of
pain deeper in the skin or in internal structures such as the spinal
cord, in combination with implanted fiber-optic systems.
CONCLUSION
We have developed multiple one-component PCL and two-
component PTL systems for photosensitizing ion channels natu-
rally present in neurons. Both of these strategies work well in vitro
and in vivo. Chemical PCLs render many types of neurons sen-
sitive to light within minutes without requiring exogenous gene
expression. They are photosensitive pharmacological agents, the
activity of which can be rapidly turned on or off with light. As
such, they provide a uniquemeans to quickly and precisely reverse
the activity of drugs in cases where simple perfusion would be
slow, tricky or impossible (e.g., the patch pipette). They are also
promising clinical candidates for treating blindness and patho-
logical pain. In contrast, PTLs are highly sophisticated molecular
tools that enable the optical control of a defined ion channel
in a targeted cell population. This ability to specifically control
a given receptor in a defined neuronal population and monitor
changes in behavior due to its activation or inhibition should
provide an unprecedented ability to uncover the functional con-
nectivity of the nervous system. Our studies will thus be crucial to
the design of novel, targeted drugs for treating neurological and
neuropsychiatric disorders.
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